Replies to post #39236 on Cel Sci Corporation (CVM)

[GD]

CVM first sells off, where is bottom? we do not now, we want to see
how strong the full subgroup data first, then argue should FDA approve
or not, IMO. By the may, CLSN first liver cancer PIII trial has a large
subgroup data with OS p 0.02, but the subgroup OS KM curves are
not impressive, so FDA told CSLN to run another PIII again to
test the subgroup patient population.